外周T细胞淋巴瘤临床治疗进展

doi:10.3760/cma.j.issn.1004-4221.2017.05.024

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (822 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Peripheral T-cell lymphoma (PTCL) is a highly specific and invasive non-Hodgkin’s lymphoma derived from mature T-cells that leave the thymus. At present, the clinical progress in PTCLs is behind that in B-cell lymphomas, and the current treatments for PTCLs have low efficacy and poor overall prognosis. Therefore, there is currently still no standard treatment for PTCL. The efficacy of the conventional CHOP chemotherapy regimen is poor, and the value of radiotherapy in early-stage PTLC patients remains to be determined. Autologous hematopoietic stem cell transplantation is the top choice for consolidation treatment for high-risk patients, but the efficacy of novel drugs for PTCLs needs to be further confirmed. In addition, PET/CT plays a more important role in predicting the prognosis of PTCLs.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wu Zheng
	Zhu Suyu

Key words： T-cell lymphomas Treatment Prognosis

Received: 03 January 2017

Corresponding Authors: Zhu Suyu,Email:zhusuyu@hnszlyy.com

Cite this article:

Wu Zheng,Zhu Suyu. Advances in therapeutic options for peripheral T-cell lymphomas[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 588-592.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.05.024 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I5/588

[1] Swerdlow SH,Campo E,Pileri SA,et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390.DOI:10.1182/blood-2016-01-643569.
[2] Savage KJ.Peripheral T-cell lymphomas[J].Blood Rev,2007,21(4):201-216.DOI:10.1016/j.blre.2007.03.001.
[3] 周立强,孙燕,谭文勇,等.非霍奇金淋巴瘤1125例临床病理分析[J].癌症进展,2006,4(5):391-397.DOI:10.3969/j.issn.1672-1535.2006.05.004.
Zhou LQ,Sun H,Tan WY,et al. Clinicopathological analysis of 1125 cases of non Hodgkin′s lymphoma[J].Cancer Prog,2006,4(5):391-397.DOI:10.3969/j.issn.1672-1535.2006.05.004.
[4] Yang QP,Zang WY,Yu JB,et alSubtype distribution of lymphomas in Southwest China:analysis of 6,382 cases using WHO classification in a single institution[J].Diagn Pathol,2011,6(77):1-7.DOI:10.1186/1746-1596-6-77.
[5] Sun J,Yang Q,Lu Z,et alDistribution of lymphoid neoplasms in China:analysis of 4,638 eases according to the World Health Organization classification[J].Am J Clin Pathol,2012.138(3):429-434.DOI:10.1309/AJCP7YLTQPUSDQ5C.
[6] Armitage J,Vose J,Weisenburger D,et al. International peripheral T-cell and natural killer/T-celllymphoma study:pathology findings and clinical outcomes[J].J Clin Oncol,2008,26(25):4124-4130.DOI:10.1200/JCO.2008.16.4558.
[7] Savage KJ,Chhanabhai M,Gascoyne RD,et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification[J].Ann Oncol,2004,15(10):1467-1475.DOI:10.1093/annonc/mdh392.
[8] Ellin F, Landstr m J,Jerkeman M,et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas:a study from the Swedish Lymphoma Registry[J].Blood,2014,124(10):1570-7.DOI:10.1182/blood-2014-04-573089.
[9] Schmitz N,Trumper L,Ziepert M,et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma:an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group[J].Blood,2010,116(18):3418-3425.DOI:10.1182/blood-2010-02-270785.
[10] Escalon MP,Liu NS,Yang Y,et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma:the M.D.Anderson Cancer Center experience[J].Cancer,2005,103(10):2091-2098.DOI:10.1002/cncr.20999.
[11] 王瑾,高磊,邱慧颖,等.Hyper CVAD/MA与CHOP/CHOP样方案治疗初发外周T胞淋巴瘤患者疗效分析[J].中华血液学杂志,2014,35(10):897-900.DOI:10.3760/cma.j.issn.0253-2727.2014.10.005.
Wang Y,Gao L,Qiu HY,et al. Efficacy analysis of Hyper CVAD/MA and CHOP/CHOP regimen in the treatment of primary peripheral T cell lymphoma[J].Chin J Hematol,2014,35(10):897-900.DOI:10.3760/cma.j.issn.0253-2727.2014.10.005.
[12] Simon A,Peoch M,Casassus P,et alUpfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/2l in newly diagnosed peripheral T cell lymphoma.Results of the randomized phase Ⅲ trial GOELAMS-LTP95[J].Br J Haematol,2010,151(2):159-166.DOI:10.1111/j.1365-2141.2010.08329.x.
[13] Mahadevan D,Unger JM,Spier CM,et al. Phase 2 trial of combined cisplatin,etoposide,gemcitabine,and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma:Southwest Oncology Group Study S0350[J].Cancer,2013,119(2):371-379.DOI:10.1002/cncr.27733.
[14] Advani RH,Ansell SM,Lechowicz MJ,et al. A phase Ⅱ study of cyclophosphamide,etoposide,vincristine and prednisone (CEOP) alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL):final results from the T-cell consortium trial[J].Br J Haematol,2016,172(4):535-544.DOI:10.1111/bjh.13855.
[15] Horwitz SM,Pinter-Brown LC,Rosen ST,et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States[J].Cancer,2016.[Epub ahead of print].DOI:10.1002/cncr.30416.
[16] Fernandes AT, Svoboda J,Nasta SD,et al. Radiation therapy in peripheral T-cell lymphoma of the head and neck[J].Blood,2013,122(21):1795.
[17] Petrich AM,Helenowski IB,Bryan LJ,et al. Factors predicting survival in peripheral T-cell lymphoma in the USA:a population-based analysis of 8802 patients in the modern era[J].Br J Haematol,2015,168(5):708-718.DOI:10.1111/bjh.13202.
[18] Weisenburger DD,Savage KJ,Harris NL,et al. Peripheral T-cell lymphoma,not otherwise specified:a report of 340 cases from the International Peripheral T-cell Lymphoma Project[J].Blood,2011,117(12):3402-3408.DOI 10.1182/blood-2010-09-310342.
[19] Deng XW,Li YX,Zhang X,et al. Treatment outcomes and prognosis of peripheral t-cell lymphoma,not otherwise specified[J].Int J Radiat Oncol Biol Phys,2015,93(3):E457.
[20] Zhang XM,Li YX,Wang WH,et al. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma[J].Eur J Haematol,2013,90(3):195-201.DOI:10.1111/ejh.12060.
[21] Briski R,Feldman AL,Bailey NG,et al. Survival in patients with limited-stage peripheral T-cell lymphomas[J].Leuk Lymphoma,2015,56(6):1665-70.DOI:10.3109/10428194.2014.963078.
[22] Chen AI,McMillan A,Negrin RS,et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma:the Stanford experience[J].Biol Blood Marrow Transplant,2008,14(7):741-747.DOI:10.1016/j.bbmt.2008.04.004.
[23] Rodríguez J,Conde E,Gutiérrez A,et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission:the Spanish Lymphoma and Autologous Transplantation Group experience[J].Ann Oncol,2007,18(4):652-7.DOI:10.1093/annonc/mdl466.
[24] d’ Amore F,Relander T,Lauritzsen GF,et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01[J].J Clin Oncol,2012,30(25):3093-3099.DOI:10.1200/JCO.2011.40.2719.
[25] Reimer P,Rüdiger T,Geissinger E,et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas:results of a prospective multicenter study[J].J Clin Oncol,2009,27(1):106-113.DOI:10.1115/1.2835644.
[26] O′Connor OA,Pro B,Pinter-Brown L,et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma:results from the pivotal PROPEL study[J].J Clin Oncol,2011,29(9):1182-1189.DOI:10.1200/JCO.2010.29.9024.
[27] Horwitz M,Advani RH,Bartlett NL,et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin[J].Blood,2014,123(20):3095-3100.DOI:10.1182/blood-2013-12-542142.
[28] Coiffier B,Pro B,Prince HM,et al. Results from a pivotal,openlabel,phase Ⅱ study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy[J].J Clin Oncol,2012,30(6):631-636.DOI:10.1200/JCO.2011.37.4223.
[29] Shi Y,Dong M,Hong X,et al. Results from a multicenter,open-label,pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J].Ann Oncol,2015,26(8):1766-1771.DOI:10.1093/annonc/mdv237.
[29] The International Non-Hodgkin′s Lymphoma Prognostic Factors Project. A predictivemodel for aggressivenon-Hodgkin′s lymphoma.the international non-hodgkin′s lymphoma prognostic factors project[J].N Engl J Med,1993,329(14):987-994.DOI:10.1056/NEJM199309303291402.
[30] Lopez-Guillermo A,Cid J,Salar A,et al. PeripheralT-cell lymphomas:initial features,natural history,and prognosticfactors in a series of 174 patients diagnosed according to the R.E.A.L.classification[J].Ann Oncol,1998,9(8):849-855.DOI:10.1023/A:1008418727472.
[31] Ansell SM,Habermann TM,Kurtin PJ,et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma[J].J Clin Oncol 1997,15(6):2296-2301.DOI:10.1200/JCO.1997.15.6.2296.
[32] Gallamini A,Stelitano C,Calvi R,et al. Peripheral T-cell lymphoma unspecified (PTCL-U):a new prognostic model from a retrospective multicentric clinical study[J].Blood,2004,103(7):2474-2479.DOI:10.1182/blood-2003-09-3080.
[33] Went P,Agostinelli C,Gallamini A,et al. Marker expression in peripheral T-cell lymphoma:a proposed clinical-pathologic prognostic score[J].J Clin Oncol,2006,24(16):2472-2479.DOI:10.1200/JCO.2005.03.6327.
[34] Vose J.International Peripheral T-cell Lymphoma (PTCL) Clinical and Pathology Review Project:poor outcome by prognostic indices and lack of efficacy with anthracyclines[J].Blood,2005,106(11):811a.
[35] Kim YR,Kim JS,Kim SJ,et al. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy[J].J Hematol Oncol,2011(4):34.DOI:10.1186/1756-8722-4-34.
[36] Niitsu N,Okamoto M,Nakamine H,et al. Clinicopathologic features and outcome of Japanese patients with peripheral T-cell lymphomas[J].Hematol Oncol,2008,26(3):152-158.DOI:10.1002/hon.853.
[37] Gutierrez-Garcia G,Garcia-Herrera A,Cardesa T,et al. Comparison of four prognostic scores in peripheral Tcell lymphoma[J].Ann Oncol,2011,22(2):397-404.DOI:10.1093/annonc/mdq359.
[38] Li YJ,Xia XY,Huang MH,et al. Prognostic value of interim and posttherapy ¹⁸F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas[J].J Nucl Med,2013,54(4):507-515.DOI:10.2967/jnumed.112.110262.
[39] Casulo C,Sch der H,Feeney J,et al¹⁸F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma[J].Leuk Lymphoma,2013,54(10):2163-2169.DOI:10.3109/10428194.2013.767901.
[40] 程娟,杨笑一,徐文贵,等.¹⁸F-FDG PE T/CT在T细胞淋巴瘤疗效评价中的临床价值[J].中华血液学杂志,2012,33(1):16-19.DOI:10.3760/cma.j.issn.0253-2727.2012.01.004.
Cheng J,Yang XY,Xu WG,et al. Clinical value of ¹⁸F-FDG PE T/CT in the evaluation of T cell lymphoma[J].Chin J Hematol,2012,33(1):16-19.DOI:10.3760/cma.j.issn.0253-2727.2012.01.004.
[41] 宋玉琴,朱军.PET/CT在淋巴瘤中的应用价值[J].中华血液学杂志,2015,35(4):280-281.DOI:10.3760/cma.j.issn.0376-2491.2012.46.001.
Song YQ,Zhu J.Application value of PET/CT in lymphoma[J].Chin J Hematol,2015,35(4):280-281.DOI:10.3760/cma.j.issn.0376-2491.2012.46.001.